| Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes C Wegler, FZ Gaugaz, TB Andersson, JR Wiśniewski, D Busch, C Gröer, ... Molecular pharmaceutics 14 (9), 3142-3151, 2017 | 111 | 2017 |
| Intracellular drug bioavailability: a new predictor of system dependent drug disposition A Mateus, A Treyer, C Wegler, M Karlgren, P Matsson, P Artursson Scientific reports 7 (1), 43047, 2017 | 70 | 2017 |
| Global variability analysis of mRNA and protein concentrations across and within human tissues C Wegler, M Ölander, JR Wiśniewski, P Lundquist, K Zettl, A Åsberg, ... NAR Genomics and Bioinformatics 2 (1), lqz010, 2020 | 49 | 2020 |
| A CRISPR-Cas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies M Karlgren, I Simoff, M Backlund, C Wegler, M Keiser, N Handin, J Müller, ... Journal of pharmaceutical sciences 106 (9), 2909-2913, 2017 | 43 | 2017 |
| Multiple-enzyme-digestion strategy improves accuracy and sensitivity of label-and standard-free absolute quantification to a level that is achievable by analysis with stable … JR Wiśniewski, C Wegler, P Artursson Journal of proteome research 18 (1), 217-224, 2018 | 42 | 2018 |
| Direct quantification of cytochromes P450 and drug transporters—a rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates F Weiß, HS Hammer, K Klein, H Planatscher, UM Zanger, A Noren, ... Drug Metabolism and Disposition 46 (4), 387-396, 2018 | 40 | 2018 |
| Subcellular fractionation of human liver reveals limits in global proteomic quantification from isolated fractions JR Wiśniewski, C Wegler, P Artursson Analytical biochemistry 509, 82-88, 2016 | 32 | 2016 |
| A comparative analysis of cytochrome P450 activities in paired liver and small intestinal samples from patients with obesity V Krogstad, A Peric, I Robertsen, MK Kringen, C Wegler, PC Angeles, ... Drug Metabolism and Disposition 48 (1), 8-17, 2020 | 31 | 2020 |
| Drug disposition protein quantification in matched human jejunum and liver from donors with obesity C Wegler, JR Wiśniewski, I Robertsen, H Christensen, J Kristoffer Hertel, ... Clinical Pharmacology & Therapeutics 111 (5), 1142-1154, 2022 | 18 | 2022 |
| Proteomics‐informed prediction of rosuvastatin plasma profiles in patients with a wide range of body weight C Wegler, L Prieto Garcia, S Klinting, I Robertsen, JR Wiśniewski, ... Clinical Pharmacology & Therapeutics 109 (3), 762-771, 2021 | 18 | 2021 |
| Short‐and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity–a non‐randomized three‐armed controlled trial KE Kvitne, I Robertsen, E Skovlund, H Christensen, V Krogstad, C Wegler, ... Clinical and Translational Science 15 (1), 221-233, 2022 | 14 | 2022 |
| Effects of Osteoporosis‐Inducing Drugs on Vitamin D‐Related Gene Transcription and Mineralization in MG‐63 and Saos‐2 Cells C Wegler, K Wikvall, M Norlin Basic & clinical pharmacology & toxicology 119 (5), 436-442, 2016 | 14 | 2016 |
| Short‐and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity KE Kvitne, V Krogstad, C Wegler, LK Johnson, MK Kringen, MH Hovd, ... British Journal of Clinical Pharmacology 88 (9), 4121-4133, 2022 | 11 | 2022 |
| Influence of proteome profiles and intracellular drug exposure on differences in CYP activity in donor-matched human liver microsomes and hepatocytes C Wegler, P Matsson, V Krogstad, J Urdzik, H Christensen, TB Andersson, ... Molecular Pharmaceutics 18 (4), 1792-1805, 2021 | 11 | 2021 |
| Expanding the efflux in vitro assay toolbox: a CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1 C Wegler, M Gazit, K Issa, S Subramaniam, P Artursson, M Karlgren Journal of Pharmaceutical Sciences 110 (1), 388-396, 2021 | 11 | 2021 |
| Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body … K Eide Kvitne, K Hole, V Krogstad, BM Wollmann, C Wegler, LK Johnson, ... European journal of clinical pharmacology 78 (8), 1289-1299, 2022 | 10 | 2022 |
| Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity KE Kvitne, A Åsberg, LK Johnson, C Wegler, JK Hertel, P Artursson, ... Clinical and Translational Science 15 (11), 2685-2696, 2022 | 7 | 2022 |
| Hepatocyte size fractionation allows dissection of human liver zonation M Ölander, C Wegler, I Flörkemeier, A Treyer, N Handin, JM Pedersen, ... Journal of Cellular Physiology 236 (8), 5885-5894, 2021 | 7 | 2021 |
| Proteomics-informed identification of luminal targets for in situ diagnosis of inflammatory bowel disease S Asad, C Wegler, D Ahl, CAS Bergström, M Phillipson, P Artursson, ... Journal of Pharmaceutical Sciences 110 (1), 239-250, 2021 | 7 | 2021 |
| Inhibition of prolyl oligopeptidase: A promising pathway to prevent the progression of age-related macular degeneration L Hellinen, A Koskela, E Vattulainen, M Liukkonen, C Wegler, A Treyer, ... Biomedicine & Pharmacotherapy 146, 112501, 2022 | 6 | 2022 |
Per ArturssonUppsala universityVerified email at farmaci.uu.se
